As new technologies increase the accuracy and clinical relevance of our delivery of radiotherapy to preclinical models of cancer, it becomes even more important that the preclinical models are also representative of the clinical scenario. There are limitations to using subcutaneous xenograft models.
In this webcast, Prof. Anthony Chalmers, Chair of Clinical Oncology at the University of Glasgow, describes the value of using orthotopic models of cancer in preclinical irradiation experiments. Specifically, he addresses two main methods: 1) genetically engineered mouse models (GEMM), in which the host immune system is also preserved; and 2) orthotopically implanted xenografts, which generally require the use of immunocompromised host animals. Prof. Chalmers provides examples of how these models are being used in Glasgow to conduct clinically relevant radiotherapy research with the SARRP system.